Vericel Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dominick C. Colangelo
- Full Time Employees
- 357
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 64 Sidney Street Cambridge MA United States of America 02139
- IPO Date
- Feb 4, 1997
- CIK
- 0000887359
- Website
- vcel.com
- Similar Companies
- Business
- Vericel Corporation Vericel Corporation (NASDAQ:VCEL) develops, manufactures, and commercializes advanced autologous cell therapies and specialty biologics for sports medicine and severe burn care markets, primarily in North America. The company offers MACI (autologous cultured chondrocytes on porcine collagen membrane), a cellularized scaffold for repairing symptomatic full-thickness cartilage defects of the knee in adults; Epicel (cultured epidermal autografts), a permanent skin replacement humanitarian use device for pediatric and adult patients with deep dermal or full-thickness burns covering 30% or more of total body surface area; and NexoBrid (anacaulase-bcdb), an exclusively licensed biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness or full-thickness thermal burns. Vericel Corporation, founded in 1989 as Aastrom Biosciences and rebranded in 2014 following its acquisition of Genzyme's cell therapy business, maintains headquarters in Cambridge, Massachusetts, with a new manufacturing and corporate headquarters facility in Burlington, Massachusetts, operational since 2025 to support expanded capacity. Recent developments include the launch of MACI Arthro for arthroscopic delivery, training of over 800 surgeons, record NexoBrid quarterly revenue growth of 38% year-over-year in Q3 2025, MACI sales force expansion completion targeted for Q4 2025, and initiation of the MACI Ankle clinical study in Q4 2025, alongside strong Q3 2025 financial results with total net revenue of $67.5 million, MACI revenue up 25% to $55.7 million, and positive net income of $5.1 million.
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More
Vericel Q1 Earnings Call Highlights
Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript
Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates
Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet
Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
Aberdeen Group plc Has $21.03 Million Stock Position in Vericel Corporation $VCEL
Analysts Set Vericel Corporation (NASDAQ:VCEL) Price Target at $56.00
Vericel Announces BARDA Award Valued at up to $197 Million for Procurement and Advanced Development of NexoBrid
Vericel Corporation $VCEL Position Increased by Congress Asset Management Co.
Intech Investment Management LLC Decreases Stock Holdings in Vericel Corporation $VCEL
Vericel Corporation (VCEL) Matches Q4 Earnings Estimates
Vericel Corporation (VCEL) Q4 2025 Earnings Call Transcript
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results
Vericel Corporation (NASDAQ:VCEL) Receives Average Recommendation of “Moderate Buy” from Analysts
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Vericel Announces Preliminary 2025 Financial Results and Business Updates
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
Vericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of “Moderate Buy” by Analysts